Ocular complications and loss of vision due to herpes zoster ophthalmicus in patients with HIV infection and a comparison with HIV-negative patients

Nithyanandam, S.; Joseph, M.; Stephen, J.
February 2013
International Journal of STD & AIDS;Feb2013, Vol. 24 Issue 2, p106
Academic Journal
The aim of the work is to describe the occurrence of ocular complications and loss of vision due to herpes zoster ophthalmicus (HZO) in HIV-positive patients who received early antiviral therapy for HZO. This is a post hoc analysis of prospectively collected data. Twenty-four HIV-positive patients with HZO were included in this report; male to female ratio was 3.8:1; mean age was 33.5 (± 14.9) years. The visual outcome was good, with 14/24 patients having 6/6 vision; severe vision loss (≤6/60) occurred in only 2/24. There was no statistical difference in the visual outcome between the HIV-positive and -negative patients (P = 0.69), although severe vision loss was more likely in HIV-infected patients. The ocular complications of HZO in HIV-infected patients were: reduced corneal sensation (17/24), corneal epithelial lesions (14/24), uveitis (12/24), elevated intraocular pressure (10/24) and extra-ocular muscle palsy (3/24). The severity of rash was similar in the two groups but multidermatomal rash occurred only in HIV-infected patients (4/24). There was no difference in the occurrence of ocular complications of HZO between HIV-positive and HIV-negative patients. HZO associated ocular complications and visual loss is low in HIV-infected patients if treated with HZO antiviral therapy and was comparable with HIV-negative patients. Early institution of HZO antiviral therapy is recommended to reduce ocular complication and vision loss.


Related Articles

  • HERPES ZOSTER OPHTHALMICUS: CLINICAL PROFILE IN ADULTS LESS THAN 30 YEARS OF AGE. Sujatha, Vijayalekshmi; Padmajothi, Mudianur Subrahmanyam; Ambika, Hariharasubramony; Sujatha, Chankramath // Our Dermatology Online / Nasza Dermatologia Online;Jan2012, Vol. 3 Issue 1, p9 

    The author discusses the article regarding herpes zoster ophthalmicus assciated with HIV which requires further specialized ophthalmic evaluation of patients, particularly in underdeveloped countries.

  • Concurrent Use of Antiretrovirals and Anticonvulsants in Human Immunodeficiency Virus (HIV) Seropositive Patients. Romanelli, Frank; Pomeroy, Claire // Current Pharmaceutical Design;Jul2003, Vol. 9 Issue 18, p1433 

    Seizure disorders may complicate HIV disease, either as a direct result of HIV or as a manifestation of a secondary opportunistic infection. Unless a reversible cause of seizure activity can be discerned, current treatment guidelines recommend the use of anticonvulsant drugs in these patients....

  • The epidemiology and clinical correlates of HIV-1 co-receptor tropism in non-subtype B infections from India, Uganda and South Africa. Ataher, Quazi; Portsmouth, Simon; Napolitano, Laura A.; Eng, Sybil; Greenacre, Anna; Kambugu, Andrew; Wood, Robin; Badal-Faesen, Sharlaa; Tressler, Randy // Journal of the International AIDS Society;2012, Vol. 15 Issue 1, p1 

    Background: The introduction of C-C chemokine receptor type-5 (CCR5) antagonists as antiretroviral therapy has led to the need to study HIV co-receptor tropism in different HIV-1 subtypes and geographical locations. This study was undertaken to evaluate HIV-1 co-receptor tropism in the...

  • The pharmacogenomics of HIV therapy. Pirmohamed, M.; Back, D.J. // Pharmacogenomics Journal;2001, Vol. 1 Issue 4, p243 

    Examines the potential areas where pharmacogenomics of HIV therapy may be of use in maximizing the efficacy and minimizing the toxicity of antiretrovirals. Classes of licensed antiretrovirals; Need for HIV patients to commence therapy with a highly active antiretroviral therapy regimen;...

  • VIRAL IMMUNITY: IFN-γ embargo. Buckland, Jenny // Nature Reviews Immunology;Apr2002, Vol. 2 Issue 4, p221 

    Discusses research being done on the antiviral interferon-γ response of HIV-infected individual. Reference to a study by M.L. Garba and colleagues, published in the 2002 issue of the 'Journal of Immunology'; Factor that caused the reduced interferon-γ responses in suppressors; Significance...

  • Care of treatment-experienced patients with HIV remains an ongoing concern.  // Infectious Disease News;Jul2009, Vol. 22 Issue 7, p14 

    The article discusses research on the use of antiretroviral therapy in treatment-experienced patients with HIV, which was presented at the 2009 American Conference for the Treatment of HIV.

  • O114. Long-term probability of detecting drug-resistant HIV in patients starting antiretroviral therapy within the first year of HIV infection. Lodi, S.; Kücherer, C.; Kran, A. M. Bakken; Masquelier, B.; Monforte, A. d'Arminio; Gill, J.; Dunn, D.; Pillay, D.; Porter, K. // Journal of the International AIDS Society;2010 Supplement 4, Vol. 13 Issue Suppl 4, p1 

    An abstract of the research paper "Long-Term Probability of Detecting Drug-Resistant HIV in Patients Starting Antiretroviral Therapy Within the First Year of HIV infection," by S. Lodi and colleagues which was presented at the Tenth International Congress on Drug Therapy in HIV Infection held at...

  • NEVIRAPINE DESENSITIZATION.  // AIDS Patient Care & STDs;Mar2000, Vol. 14 Issue 3, p169 

    Reports that doctors in France were able to desensitize HIV patients who developed severe hypersensitivity to nevirapine. Use of nevirapine as part of a combination antiretroviral therapy; Desensitization of HIV patients after being off nevirapine.

  • Antiviral Effect and Pharmacokinetic Interaction between Nevirapine and Indinavir in Persons Infected with Human Immunodeficiency Virus Type 1. Murphy, Robert L.; Sommadossi, Jean-Pierre; Lamson, Michael; Hall, David B.; Myers, Maureen; Dusek, Alex // Journal of Infectious Diseases;5/1/99, Vol. 179 Issue 5, p1116 

    Discusses the antiviral effect and pharmacokinetic interaction between Nevirapine and Indinavir in persons infected with human immunodeficiency virus (HIV) type 1. Sevenfold difference among subjects in indinavir area under the curve (AUC); Significant correlation between indinavir AUC, minimum...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics